Numinus Wellness

The story of Numinus Wellness begins with its founder, Payton Nyquvest, and his personal, life-saving experiences with various therapy methods. Drawing from his background in finance, Nyquvest, along with co-founder Stacey Wallin, launched Numinus in 2019 to increase access to psychedelic-assisted therapies. Their goal was to build an ecosystem for mental wellness that combined psychedelic production, research, and clinical care. Just a year after its founding, Numinus went public on the TSX exchange on May 20, 2020. This move provided the capital to advance its mission. Later that year, the company began cultivating psilocybin mushrooms at its Health Canada-licensed lab, aiming to develop standardized, natural alternatives to the synthetic psilocybin used in research. This step was crucial for creating a safe and evidence-based supply for future therapies. A significant turning point came in June 2022, when Numinus completed the acquisition of Novamind, a U.S.-based mental health company specializing in psychedelic medicine. This acquisition, valued at approximately $20 million, expanded Numinus's footprint into the United States and grew its network to 13 wellness clinics and four research sites. The deal was a strategic play to combine complementary research capabilities and establish a strong foothold in the American market, which has a significant history of psychedelic research.